Detail akcie Kalaris Therap Rg online

Business Summary: Kalaris Therapeutics, Inc., formerly AlloVir, Inc., is a clinical-stage biopharmaceutical company engaged in the development and commercialization of treatments for prevalent retinal diseases. The Company is focused on the development of TH103, a differentiated anti-vascular endothelial growth factor (VEGF) investigational therapy. TH103 is a fully humanized, recombinant fusion protein that acts against VEGF as a decoy receptor and has been specifically engineered for potentially improved VEGF inhibition and longer retention in the retina. TH103 is being evaluated in an ongoing, Phase I clinical trial for the treatment of neovascular age-related macular degeneration (nAMD), with plans to develop TH103 for additional neovascular and exudative diseases of the retina such as diabetic macular edema (DME), and retinal vein occlusion (RVO).
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Kalaris Therapeutics Inc revenues was not reported. Net loss decreased 55% to $33.4M. Lower net loss reflects Research and development decrease of 54% to $23.6M (expense), Stock-based Compensation in SGA decrease of 81% to $1M (expense), G/L on debt restructuring decrease of 86% to $186K (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$38.50 to -$3.76.